Diagnostic and pharmaceutical companies sign distribution agreement for point-of-care celiac disease test.
Augurix Diagnostics and Tillotts Pharma have entered into a commercialization agreement for Simtomax - a point-of-care test for screening celiac disease. The agreement grants Tillotts the exclusive right to distribute and supply Simtomax in dedicated key European markets.
The pocket-sized medical device will allow healthcare professionals, pharmacies and retail clinics to test patients for celiac disease and get immediate results. With a drop of blood, Simtomax can test for:
Immunoglobulin-A (IgA) anti-deamidated gliadin peptide
Immunoglobulin-G (IgG) anti-deamidated gliadin peptide
Total IgA level
The test is intended to be a first step in the diagnosis of celiac disease. Augurix recommends that a diagnosis be confirmed through intestinal biopsy.
While the announcement noted that Tillotts will be targeting European markets, it did not indicate any plans to bring the test to the U.S.
For more information, see the press release.